Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 1;23(15):4846-4859.
doi: 10.1016/j.bmc.2015.05.028. Epub 2015 May 23.

Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors

Hiroaki Yamagishi  1 , Shohei Shirakami  2 , Yutaka Nakajima  2 , Akira Tanaka  2 , Fumie Takahashi  2 , Hisao Hamaguchi  2 , Keiko Hatanaka  2 , Ayako Moritomo  2 , Masamichi Inami  2 , Yasuyuki Higashi  2 , Takayuki Inoue  3
Affiliations

Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors

Hiroaki Yamagishi et al. Bioorg Med Chem. .

Abstract

Because Janus kinases (JAKs) play a crucial role in cytokine-mediated signal transduction, JAKs are an attractive target for the treatment of organ transplant rejection and autoimmune diseases such as rheumatoid arthritis (RA). To identify JAK inhibitors, we focused on the 1H-pyrrolo[2,3-b]pyridine derivative 3, which exhibited moderate JAK3 and JAK1 inhibitory activities. Optimization of 3 identified the tricyclic imidazo-pyrrolopyridinone derivative 19, which exhibited potent JAK3 and JAK1 inhibitory activities (IC50=1.1 nM, 1.5 nM, respectively) with favorable metabolic stability.

Keywords: Autoimmune diseases; IL-2; Immunomodulator; Janus kinase inhibitor; Organ transplant rejection.

PubMed Disclaimer

MeSH terms

LinkOut - more resources